Biotech Assistant
Share useful research with your peers
in · Share on LinkedIn ↗
BIOTECH ASSISTANT / FIELD NOTES

Certara introduces an integrated development-strategy offering for emerging biotechs

Company / institutional announcement · Certara

Source published: · Event / reporting date: 2026-06-22

Site published: 2026-11-04 · Updated: 2026-11-04

Explore this article with AI

This source is linked automatically. Choose a question to get started.

Ask AI ↗
Findings and limitationsIndustry implicationsRelated developments

What changed

Certara launched Bio Venture Catalyst, bringing together scientific development, regulatory, commercial, and investor-oriented strategy. The announcement includes model-informed development support and asset prioritization. The offering is a consulting service; its stated aims do not demonstrate improved clinical outcomes or guarantee financing.

Why it may matter

Potential business relevance: track disclosed capabilities or development plans; independent validation and project-specific applicability still require review.

The interpretation above is analysis, not a conclusion attributed to the original source.

Read the original source ↗

Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections

Clinical Pharmacology & Model-Informed Development

Follow the evidence

Companies mentionedCertara ↗
Explore field companies →Explore literature →

Related updates

Cleveland Clinic

Lp(a)HORIZON reports neutral cardiovascular outcomes despite substantial pelacarsen biomarker reduction

Cleveland Clinic reported that the Phase 3 Lp(a)HORIZON trial found no reduction in major cardiovascular events with the antisense drug pelacarsen after median follow-up of 4.7 years. Event rates were 12.3% with pelacarsen and 12.1% with placebo, despite substantial Lp(a) lowering. The findings concern patients with established cardiovascular disease and do not settle outcomes for other Lp(a)-lowering modalities.

Oligonucleotide Therapeutics & Delivery Clinical Pharmacology & Model-Informed DevelopmentAsk AI ↗
European Journal of Drug Metabolism and Pharmacokinetics

Progesterone PopPK study combines machine-learning screening with conventional covariate modeling

A study in European Journal of Drug Metabolism and Pharmacokinetics modeled subcutaneous aqueous progesterone using single-dose crossover data from 50 healthy Chinese postmenopausal women. Machine-learning approaches screened potential covariates before conventional PopPK evaluation. Height and body-weight effects remained statistically identifiable but had limited clinical significance. Simulated repeated-dose exposure is model-derived, rather than an observed efficacy outcome in fertility patients.

Clinical Pharmacology & Model-Informed DevelopmentAsk AI ↗
PharmaIN Corporation

PharmaIN reports Phase 1 multiple-dose PHIN-214 findings in cirrhosis

On November 5, PharmaIN reported conference findings from PHIN-001: 12 participants with Child-Pugh B cirrhosis received PHIN-214; 10 completed 28 days. The issuer described Grade 1–2 treatment-related adverse events and exploratory renal, hemodynamic and PK findings. The ongoing small Phase 1 study does not establish clinical benefit. This is a company conference announcement, not a peer-reviewed paper.

Clinical Pharmacology & Model-Informed DevelopmentAsk AI ↗

Continue your research

All company profiles, filters, and comparisons are open. Sign in for private saves and member discussions.

Open full company map ↗
AI assistant ↗